このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Jacobson Pharma 配当金

配当金基準チェック /36

Jacobson Pharmaは配当を支払う会社で、現在の利回りは7.63%ですが、利益によって十分にカバーされています。次の支払い日は 4th October, 2024で、権利落ち日は3rd September, 2024 。

主要情報

8.3%

配当利回り

57%

配当性向

業界平均利回り	3.7%
次回配当支払日	04 Oct 24
配当落ち日	03 Sep 24
一株当たり配当金	n/a
一株当たり利益	HK$0.094
3年後の配当利回り予想	n/a

最近の配当金アップデート

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27

Recent updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03

配当金の支払いについて

決済の安定と成長

配当データの取得

安定した配当: 2633は 10 年未満配当金を支払っており、この間、支払額は変動性が高かった。

増加する配当: 2633の配当金は増加していますが、同社は8年間しか配当金を支払っていません。

配当利回り対市場

Jacobson Pharma 配当利回り対市場

2633 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (2633)	8.3%
市場下位25% (HK)	3.4%
市場トップ25% (HK)	8.0%
業界平均 (Pharmaceuticals)	3.7%
3年後のアナリスト予想 (2633)	n/a

注目すべき配当: 2633の配当金 ( 8% ) はHong Kong市場の配当金支払者の下位 25% ( 3.25% ) よりも高くなっています。

高配当: 2633の配当金 ( 8.59% ) はHong Kong市場 ( 7.84% ) の配当支払者の中で上位 25% に入っています。

株主への利益配当

収益カバレッジ: 2633の配当金は、合理的な配当性向 ( 56.7% ) により、利益によって賄われています。

株主配当金

キャッシュフローカバレッジ: 2633の現金配当性向を計算して、配当金の支払いがキャッシュフローでカバーされているかどうかを判断するにはデータが不十分です。

Jacobson Pharma 配当金

配当金 基準チェック /36

主要情報

最近の配当金アップデート

Upcoming dividend of HK$0.025 per share at 7.7% yield

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended September 30, 2023, Payable on 10 January 2024

Upcoming dividend of HK$0.024 per share at 5.3% yield

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2023, Payable on 1 September 2023

Upcoming dividend of HK$0.028 per share

Recent updates

Jacobson Pharma Corporation Limited, Annual General Meeting, Aug 28, 2024

Full year 2024 earnings released: EPS: HK$0.11 (vs HK$0.13 in FY 2023)

Jacobson Pharma Corporation Limited has completed a Follow-on Equity Offering in the amount of HKD 39.6 million.

New minor risk - Shareholder dilution

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Upcoming dividend of HK$0.025 per share at 7.7% yield

First half 2024 earnings released: EPS: HK$0.053 (vs HK$0.077 in 1H 2023)

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

New minor risk - Earnings quality

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended September 30, 2023, Payable on 10 January 2024

Jacobson Pharma Corporation Limited to Report Q2, 2024 Results on Nov 24, 2023

New minor risk - Share price stability

Now 40% undervalued after recent price drop

Upcoming dividend of HK$0.024 per share at 5.3% yield

Jacobson Pharma Corporation Limited, Annual General Meeting, Aug 01, 2023

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2023, Payable on 1 September 2023

Full year 2023 earnings released: EPS: HK$0.13 (vs HK$0.093 in FY 2022)

Jacobson Pharma Corporation Limited to Report Fiscal Year 2023 Results on Jun 15, 2023

Upcoming dividend of HK$0.028 per share

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 29 December 2022

First half 2023 earnings released: EPS: HK$0.071 (vs HK$0.042 in 1H 2022)

Less than half of directors are independent

Jacobson Pharma Corporation Limited to Report First Half, 2023 Results on Nov 25, 2022

Upcoming dividend of HK$0.027 per share

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Jacobson Pharma Corporation Limited Approves Final Dividend for the Year Ended 31 March 2022

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma Corporation Limited, Annual General Meeting, Sep 23, 2022

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Chairman recently bought HK$1.6m worth of stock

Full year 2022 earnings released

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2022, Payable on 18 October 2022

Jacobson Pharma Corporation Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Chairman recently bought HK$237k worth of stock

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Chairman recently bought HK$341k worth of stock

Chairman recently bought HK$377k worth of stock

Upcoming dividend of HK$0.012 per share

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

First half 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of HK$0.015 per share

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Full year 2021 earnings released: EPS HK$0.091 (vs HK$0.11 in FY 2020)

The board of Jacobson Pharma Corporation Limited (SEHK:2633) completed the spin off of an unknown stake of Branded healthcare business.

Independent Non-Executive Director recently bought HK$144k worth of stock

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Investor sentiment deteriorated over the past week

New 90-day low: HK$1.07

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Second quarter 2021 earnings released: EPS HK$0.027

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

New 90-day high: HK$1.20

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Second quarter 2021 earnings released: EPS HK$0.027

New 90-day low: HK$1.11

Jacobson Pharma Corporation Limited to Report Q2, 2021 Results on Nov 27, 2020

Price target lowered to HK$1.65

New 90-day low - HK$1.20

配当金の支払いについて

決済の安定と成長

配当利回り対市場

株主への利益配当

配当金基準チェック /36